LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Arcus Biosciences Inc

Geschlossen

BrancheGesundheitswesen

8.55 0.12

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.41

Max

8.86

Schlüsselkennzahlen

By Trading Economics

Einkommen

-18M

-112M

Verkäufe

2M

28M

EPS

-1.14

Gewinnspanne

-400

Angestellte

627

EBITDA

-34M

-122M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+237.11% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-34M

932M

Vorheriger Eröffnungskurs

8.43

Vorheriger Schlusskurs

8.55

Nachrichtenstimmung

By Acuity

50%

50%

173 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

Arcus Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2025, 22:52 UTC

Ergebnisse
Wichtige Markttreiber

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. Mai 2025, 20:37 UTC

Top News
Ergebnisse

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. Mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. Mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. Mai 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. Mai 2025, 22:46 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 21:58 UTC

Ergebnisse

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. Mai 2025, 21:24 UTC

Ergebnisse

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. Mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. Mai 2025, 20:54 UTC

Market Talk
Ergebnisse

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. Mai 2025, 20:54 UTC

Ergebnisse

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. Mai 2025, 20:51 UTC

Ergebnisse

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. Mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Mai 2025, 20:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. Mai 2025, 20:50 UTC

Ergebnisse

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. Mai 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. Mai 2025, 20:25 UTC

Ergebnisse

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer-Vergleich

Kursveränderung

Arcus Biosciences Inc Prognose

Kursziel

By TipRanks

237.11% Vorteil

12-Monats-Prognose

Durchschnitt 28.89 USD  237.11%

Hoch 46 USD

Tief 14 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arcus Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

10

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

8.01 / 8.75Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Neutral Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

173 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.